The UK CBD market has a serious signal-to-noise problem. Walk into any health food shop or scroll through any wellness platform and you’ll find shelves and listings crowded with products making near-identical claims: “full spectrum,” “lab tested,” “premium quality,” with almost nothing to distinguish one from another at the point of purchase. OriginalsCBD is one of the rare exceptions, and the reason isn’t marketing. It’s what happens when the person designing the products actually grows the plant.
Who Is Behind OriginalsCBD and Why It Matters
Founder Sean brings over 15 years of hands-on hemp cultivation experience to the brand. That’s not a minor detail. In an industry where most CBD companies are essentially procurement operations, sourcing bulk extract, white-labelling, and attaching a logo, having a founder who understands cultivation at the plant level changes what gets prioritised in product development.
The difference shows up in the details: the curing practices applied to the flower, the decision to avoid adding synthetic terpenes back into processed extract, and the strain selection process. These aren’t marketing decisions. They’re the instincts of someone who has spent a decade and a half understanding what makes hemp actually good, rather than just good enough to sell.
The Full-Spectrum Question: Why It’s More Complicated Than Brands Admit
Most CBD flower shops in the UK talking about “full spectrum” are relying on the fact that most consumers don’t press them on what that actually means. In practical terms, full-spectrum extract retains the complete cannabinoid and terpene profile of the original plant, including CBG, CBN, CBC, trace THC within legal limits, and dozens of aromatic compounds, rather than stripping it down to isolated CBD and rebuilding it with additives.
The reason this matters isn’t just philosophical purity. The entourage effect, the theory that these compounds interact synergistically to produce effects more nuanced than any single molecule alone, is still being studied, but the evidence base is growing. A 2020 study published in the European Journal of Pain found that full-spectrum hemp extract outperformed CBD isolate in a rat model of chronic inflammation. Human trials are more limited, but the gap between “we don’t know yet” and “it doesn’t matter” is significant.
OriginalsCBD’s position on this, no added terpenes, no isolates, natural flowers only, is the harder commercial path. It means the product can’t be standardised as easily, batches will vary slightly by harvest, and the margin is thinner. That they’ve maintained this position anyway is a credibility signal worth paying attention to.
How OriginalsCBD Compares to Competitors?
Take Blessed CBD, one of the most frequently recommended brands on UK review aggregators. Their oils are competently made and their testing documentation is accessible, but the product range leans heavily on standardised extract, consistent and reliable, but without the strain-specific character that OriginalsCBD’s flower range delivers.
Provacan, a well-funded brand with clinical research partnerships, occupies a different position, more pharmaceutical in orientation, with products that prioritise dosing precision over complexity of profile. For someone managing a specific condition under medical guidance, that precision has value. For someone seeking a more holistic, whole-plant experience, it can feel reductive.
Where OriginalsCBD fits is at the intersection of artisan craft and serious quality standards. It’s not competing on clinical precision, and it’s not competing on price. It’s competing on what a product made by someone who genuinely knows hemp looks, smells, and works like, and in that dimension, it’s hard to match.
The Testing Transparency Gap
The UK CBD market is operating in a genuinely difficult regulatory environment. The Food Standards Agency has required novel food authorisation for CBD products sold as supplements since 2021, and the list of approved applications is still being processed. Consumers can track the current state of FSA-validated CBD applications directly on the official FSA novel food page: FSA CBD Novel Food Applications.
In that context, a brand’s commitment to batch-specific third-party lab testing isn’t just good practice. It’s one of the only reliable tools consumers have for making informed decisions. Many brands publish a single certificate of analysis on their website and treat it as a blanket endorsement of their entire range. OriginalsCBD publishes batch-specific results, which means what you’re buying has actually been tested, not just a representative sample from an earlier production run. In a market where mislabelling remains documented and widespread, this distinction is substantive. The Centre for Medicinal Cannabis published a report finding significant labelling inaccuracies across UK CBD products, which puts the importance of batch-level testing in sharp relief: CMC UK CBD Report.
What Customers Actually Report
The pattern in OriginalsCBD’s reviews is notably different from the vague five-star impressionism common on CBD brand pages. Customers are specific: they describe particular strains by name, compare terpene profiles to products they’ve encountered elsewhere, note the quality of curing, comment on weight accuracy. This is the vocabulary of people who know what they’re evaluating, not casual first-timers leaving a courtesy review.
One recurring theme is performance relative to price point. Multiple reviewers noted that products at OriginalsCBD’s lower price tier, the smalls and trim, outperformed expectations in a way that suggests the quality floor of the range is higher than the price implies.
Where OriginalsCBD Has Room to Grow
Fairness requires acknowledging the gaps. The product range, while intentionally curated, is narrower than some competitors. Customers looking for gummies, capsules, vape products, or a wide rotating library of strains may find the selection limiting. The website experience, while functional, doesn’t match the sophistication of the product itself, a minor point, but one worth noting for a brand at this quality level.
There is also the inherent volatility of a small, cultivation-adjacent business. Seasonal strain availability and batch variation, while markers of genuine craft, mean the specific product you buy today may not be available in identical form next season. For consumers who need absolute consistency, this is a meaningful consideration.
The Verdict
OriginalsCBD is what you get when real cultivation expertise is applied to a market that has been largely defined by procurement and packaging. It is not the largest brand, the flashiest, or the cheapest. It is, by most substantive measures, one of the most credible, and in a market still finding its footing under evolving FSA guidance, credibility is the scarcest resource of all.
For UK consumers who want a CBD product built on actual knowledge of the plant rather than marketing copy about it, this is the clearest recommendation available.
Lynn Martelli is an editor at Readability. She received her MFA in Creative Writing from Antioch University and has worked as an editor for over 10 years. Lynn has edited a wide variety of books, including fiction, non-fiction, memoirs, and more. In her free time, Lynn enjoys reading, writing, and spending time with her family and friends.
